These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30772772)

  • 1. Alpha-cyclodextrin inhibits cholesterol crystal-induced complement-mediated inflammation: A potential new compound for treatment of atherosclerosis.
    Pilely K; Bakke SS; Palarasah Y; Skjoedt MO; Bartels ED; Espevik T; Garred P
    Atherosclerosis; 2019 Apr; 283():35-42. PubMed ID: 30772772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclodextrin Reduces Cholesterol Crystal-Induced Inflammation by Modulating Complement Activation.
    Bakke SS; Aune MH; Niyonzima N; Pilely K; Ryan L; Skjelland M; Garred P; Aukrust P; Halvorsen B; Latz E; Damås JK; Mollnes TE; Espevik T
    J Immunol; 2017 Oct; 199(8):2910-2920. PubMed ID: 28855312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release.
    Samstad EO; Niyonzima N; Nymo S; Aune MH; Ryan L; Bakke SS; Lappegård KT; Brekke OL; Lambris JD; Damås JK; Latz E; Mollnes TE; Espevik T
    J Immunol; 2014 Mar; 192(6):2837-45. PubMed ID: 24554772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol Crystals Activate the Lectin Complement Pathway via Ficolin-2 and Mannose-Binding Lectin: Implications for the Progression of Atherosclerosis.
    Pilely K; Rosbjerg A; Genster N; Gal P; Pál G; Halvorsen B; Holm S; Aukrust P; Bakke SS; Sporsheim B; Nervik I; Niyonzima N; Bartels ED; Stahl GL; Mollnes TE; Espevik T; Garred P
    J Immunol; 2016 Jun; 196(12):5064-74. PubMed ID: 27183610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconstituted High-Density Lipoprotein Attenuates Cholesterol Crystal-Induced Inflammatory Responses by Reducing Complement Activation.
    Niyonzima N; Samstad EO; Aune MH; Ryan L; Bakke SS; Rokstad AM; Wright SD; Damås JK; Mollnes TE; Latz E; Espevik T
    J Immunol; 2015 Jul; 195(1):257-64. PubMed ID: 26026058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.
    Zimmer S; Grebe A; Bakke SS; Bode N; Halvorsen B; Ulas T; Skjelland M; De Nardo D; Labzin LI; Kerksiek A; Hempel C; Heneka MT; Hawxhurst V; Fitzgerald ML; Trebicka J; Björkhem I; Gustafsson JÅ; Westerterp M; Tall AR; Wright SD; Espevik T; Schultze JL; Nickenig G; Lütjohann D; Latz E
    Sci Transl Med; 2016 Apr; 8(333):333ra50. PubMed ID: 27053774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation by cholesterol crystals triggers a subsequent cytokine response.
    Niyonzima N; Halvorsen B; Sporsheim B; Garred P; Aukrust P; Mollnes TE; Espevik T
    Mol Immunol; 2017 Apr; 84():43-50. PubMed ID: 27692470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Therapy of Atherosclerosis by a Broad-Spectrum Reactive Oxygen Species Scavenging Nanoparticle with Intrinsic Anti-inflammatory Activity.
    Wang Y; Li L; Zhao W; Dou Y; An H; Tao H; Xu X; Jia Y; Lu S; Zhang J; Hu H
    ACS Nano; 2018 Sep; 12(9):8943-8960. PubMed ID: 30114351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Reactive Protein Binds to Cholesterol Crystals and Co-Localizes with the Terminal Complement Complex in Human Atherosclerotic Plaques.
    Pilely K; Fumagalli S; Rosbjerg A; Genster N; Skjoedt MO; Perego C; Ferrante AMR; De Simoni MG; Garred P
    Front Immunol; 2017; 8():1040. PubMed ID: 28900428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage Membrane-Encapsulated Dopamine-Modified Poly Cyclodextrin Multifunctional Biomimetic Nanoparticles for Atherosclerosis Therapy.
    Zhu L; Zhong Y; Yan M; Ni S; Zhao X; Wu S; Wang G; Zhang K; Chi Q; Qin X; Li C; Huang X; Wu W
    ACS Appl Mater Interfaces; 2024 Jun; 16(25):32027-32044. PubMed ID: 38867426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-density lipoprotein reduces the human monocyte inflammatory response.
    Murphy AJ; Woollard KJ; Hoang A; Mukhamedova N; Stirzaker RA; McCormick SP; Remaley AT; Sviridov D; Chin-Dusting J
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2071-7. PubMed ID: 18617650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of von Willebrand Factor to Complement C1q Decreases the Phagocytosis of Cholesterol Crystals and Subsequent IL-1 Secretion in Macrophages.
    Donat C; Thanei S; Trendelenburg M
    Front Immunol; 2019; 10():2712. PubMed ID: 31824501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclodextrins: Potential therapeutics against atherosclerosis.
    Mahjoubin-Tehran M; Kovanen PT; Xu S; Jamialahmadi T; Sahebkar A
    Pharmacol Ther; 2020 Oct; 214():107620. PubMed ID: 32599008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis.
    Dou Y; Chen Y; Zhang X; Xu X; Chen Y; Guo J; Zhang D; Wang R; Li X; Zhang J
    Biomaterials; 2017 Oct; 143():93-108. PubMed ID: 28778000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Reversal of Atherosclerosis by FDA-Approved Compound that Transforms Cholesterol into an Anti-Inflammatory "Prodrug".
    Mendelsohn AR; Larrick JW
    Rejuvenation Res; 2016 Jun; 19(3):252-5. PubMed ID: 27241174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclodextrin-mediated conjugation of macrophage and liposomes for treatment of atherosclerosis.
    Gao C; Liu C; Chen Q; Wang Y; Kwong CHT; Wang Q; Xie B; Lee SMY; Wang R
    J Control Release; 2022 Sep; 349():2-15. PubMed ID: 35779655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol crystal formation is a unifying pathogenic mechanism in the development of diabetic retinopathy.
    Hammer SS; Dorweiler TF; McFarland D; Adu-Agyeiwaah Y; Mast N; El-Darzi N; Fortmann SD; Nooti S; Agrawal DK; Pikuleva IA; Abela GS; Grant MB; Busik JV
    Diabetologia; 2023 Sep; 66(9):1705-1718. PubMed ID: 37311879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity.
    Kim H; Han J; Park JH
    J Control Release; 2020 Mar; 319():77-86. PubMed ID: 31843641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viewing atherosclerosis through a crystal lens: How the evolving structure of cholesterol crystals in atherosclerotic plaque alters its stability.
    Nidorf SM; Fiolet A; Abela GS
    J Clin Lipidol; 2020; 14(5):619-630. PubMed ID: 32792218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of oral cyclodextrins: effects of hydroxypropyl cyclodextrins, cyclodextrin sulfates and cationic cyclodextrins on steroid balance in rats.
    Gerloczy A; Hoshino T; Pitha J
    J Pharm Sci; 1994 Feb; 83(2):193-6. PubMed ID: 8169787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.